The CCRC research teams have conducted clinical studies for monoclonal antibody treatments — with traditional IV administration and an intramuscular shot administration — as well as studies of oral medications to determine if they could effectively prevent progression of the disease, and antiviral oral medications in development for the treatment of COVID-19 infection. Study sponsors cover all clinical study costs and participants will not be charged for any service. The CCRC is not a hospital and will only have participation from volunteers that fit the study criteria and fully consent to participation.
Interested in volunteering for one of our studies? Contact us to see if you qualify.
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19.
This study aimed to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. This study enrolled adults who had recently tested positive for SARS-COV-2 and had experienced at least one related mild or moderate symptom. Patients between the ages of 18-59 were required to have at least one pre-existing risk factor to be eligible.
A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk non-hospitalized patients
This was a phase 3 study that compared the administration route of an intramuscular shot to IV infusion of sotrovimab, a monoclonal antibody with FDA emergency use authorization, for the early treatment of non-hospitalized patients with COVID-19.
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19
The REGN 2067 study tested an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they could: decrease the amount of virus in the body; decrease the length of time the virus is in the body; and decrease the length and severity of COVID-19 illness.
A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
The primary objectives of this study were to evaluate the efficacy of remdesivir (RDV) in reducing the rate of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.
Fluvoxamine for Early Treatment of COVID-19: A Fully-remote, Randomized Placebo Controlled Trial
The purpose of this research study was to determine if a drug called fluvoxamine could be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 was considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study was fully-remote, which means that there is no face-to-face contact; study materials including study drug were shipped to participants' houses. People around the United States and Canada could participate.
This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19.
This study was Phase 2 of Merck’s MK-4482-002 study, under Ridgeback Therapeutics. Preliminary results show a reduction in infection time with no adverse events reported that were study drug related.